Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCBX.L Regulatory News (CBX)

  • There is currently no data for CBX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update on ingestibles product range

22 Apr 2022 18:04

RNS Number : 1183J
Cellular Goods PLC
22 April 2022
 

The information contained within this announcement is deemed by the Company to constitute inside

information stipulated under the Market Abuse Regulation (EU) No. 596/2014, as retained as part of

the law of England and Wales. Upon the publication of this announcement via the Regulatory

Information Service, this inside information is now considered to be in the public domain.

 

 

Press release

 

22 April 2022

 

Cellular Goods PLC

 

('Cellular Goods' or 'the Company')

 

Update on ingestibles product range

 

Further to the announcement of 13 April 2022, the Company has now received correspondence from Trading Standards and has agreed to suspend sales of its ingestibles range with immediate effect.

 

The Company is disappointed with this development and will continue to engage with the Food Standards Agency (FSA) given its ingestible products are identical to products which are entitled to remain on the market.

 

While the Company believes that ingestibles are an important part of the overall market, Cellular's product marketing activity to date has focused on the non-ingestible products in the Company's 'Look Better' skincare range which remains unaffected.

 

Anna Chokina, Chief Executive Officer of Cellular Goods, said: "We are disappointed by the FSA's stance. We will continue to engage with the regulator as we believe our products are safe, of a high quality and appropriate to be on the market. We hope the matter can be resolved soon."

 

 

For further information please contact:

Cellular Goods

Anna Chokina

Chief Executive

Neil Thapar

Investor Relations

via Tancredi +44 207 887 7633

 

+44 787 645 5323

Tennyson Securities

Corporate Broker

Peter Krens

 

+44 207 186 9030

Novum Securities

Corporate Broker

Colin Rowbury

Jon Belliss

 

 

+44 207 399 9427 

Tancredi Intelligent Communication

Media Relations

Helen Humphrey

Gabriela Amaya Garcia

Charlie Hobbs

cellulargoods@tancredigroup.com

 

+44 744 922 6720

+44 791 503 5294

+44 789 755 7112

 

About Cellular Goods PLC:

Cellular Goods is a UK-based wellness company that provides premium products based on lab-made cannabinoids. It was established in August 2018 to develop efficacy-led and research-backed cannabinoid-powered wellness products. The initial focus is on three product verticals: Function Better, Feel Better and Look Better. These three verticals encompass Cellular Goods' premium CBG skincare and CBD ingestible and topical athletic recovery products, with the first products launched in December 2021 initially through the Company's website. The Company's shares are listed on the main market of the London Stock Exchange. www.cellular-goods.com 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDSEEFWEEESESL
Date   Source Headline
28th Mar 20224:35 pmRNSPrice Monitoring Extension
28th Mar 202211:00 amRNSPrice Monitoring Extension
22nd Mar 20227:00 amRNSDirectorate change
14th Mar 20224:41 pmRNSSecond Price Monitoring Extn
14th Mar 20224:36 pmRNSPrice Monitoring Extension
14th Mar 20222:05 pmRNSSecond Price Monitoring Extn
14th Mar 20222:00 pmRNSPrice Monitoring Extension
14th Mar 20227:00 amRNSLaunch of outdoor marketing campaign
8th Mar 202211:03 amRNSShare purchase by CEO
7th Mar 202211:05 amRNSSecond Price Monitoring Extn
7th Mar 202211:00 amRNSPrice Monitoring Extension
4th Mar 20224:41 pmRNSSecond Price Monitoring Extn
4th Mar 20224:36 pmRNSPrice Monitoring Extension
2nd Mar 20227:00 amRNSExercise of Warrants
1st Mar 20227:00 amRNSLaunch of Rejuvenating Cannabinoid Face Serum
23rd Feb 20224:41 pmRNSSecond Price Monitoring Extn
23rd Feb 20224:36 pmRNSPrice Monitoring Extension
23rd Feb 20222:06 pmRNSSecond Price Monitoring Extn
23rd Feb 20222:01 pmRNSPrice Monitoring Extension
21st Feb 202211:05 amRNSSecond Price Monitoring Extn
21st Feb 202211:00 amRNSPrice Monitoring Extension
21st Feb 20229:05 amRNSSecond Price Monitoring Extn
21st Feb 20229:00 amRNSPrice Monitoring Extension
21st Feb 20227:00 amRNSStrategy and trading update
2nd Feb 20227:00 amRNSWhite paper on cannabinoids and skin aging
7th Jan 20221:00 pmRNSResults of Annual General Meeting
15th Dec 20217:00 amRNSAnnual General Meeting update
8th Dec 20217:00 amRNSGrant of Options to CEO
6th Dec 20211:57 pmRNSPosting of Annual Report and Notice of AGM
6th Dec 20217:00 amRNSAppointment of new CEO
3rd Dec 20217:00 amRNSAnnual results
1st Dec 20217:00 amRNSLaunch of inaugural products & ecommerce platform
11th Nov 20217:00 amRNSAdvertising and PR agencies appointed
8th Nov 20212:05 pmRNSSecond Price Monitoring Extn
8th Nov 20212:00 pmRNSPrice Monitoring Extension
8th Nov 202111:05 amRNSSecond Price Monitoring Extn
8th Nov 202111:00 amRNSPrice Monitoring Extension
1st Nov 20217:00 amRNSGrant of Share Options and update on warrants
4th Oct 20219:06 amRNSSecond Price Monitoring Extn
4th Oct 20219:00 amRNSPrice Monitoring Extension
4th Oct 20217:00 amRNSDirector dealings & TR1 notification
16th Aug 20217:00 amRNSSupply agreement signed with Chanelle McCoy Health
2nd Aug 20217:00 amRNSShare disposal by significant shareholder
28th Jul 20212:06 pmRNSSecond Price Monitoring Extn
28th Jul 20212:00 pmRNSPrice Monitoring Extension
10th Jun 20217:00 amRNSSupply agreement signed with Willow Biosciences
25th May 20217:00 amRNSCellular Goods Interim Results
6th May 20217:00 amRNSGrant of Warrants and Extension of Exercise Period
20th Apr 20212:00 pmRNSPrice Monitoring Extension
12th Apr 20217:00 amRNSCellular Goods boosts team with five appointments

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.